Education
About Us
Working with TipRanks
Follow Us
Ionis Pharmaceuticals (IONS)
NASDAQ:IONS
IONS Stock Chart & Stats
Day’s Range― - ―
52-Week Range$23.95 - $50.43
Previous CloseN/A
Volume126.35K
Average Volume (3M)1.95M
Market Cap
$6.72B
Enterprise Value$6.89B
Total Cash (Recent Filing)$2.15B
Total Debt (Recent Filing)$1.41B
Price to Earnings (P/E)―
Beta0.82
Next Earnings
Oct 30, 2025EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.70
Shares Outstanding159,391,240
10 Day Avg. Volume1,880,218
30 Day Avg. Volume1,947,094
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market Cap1.02
Enterprise Value/Revenue9.60
Enterprise Value/Gross Profit9.82
Enterprise Value/Ebitda-18.29
Forecast
1Y Price Target
$61.83Price Target Upside44.63% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
Bulls Say, Bears Say
Bulls Say
FDA ApprovalFDA approval of Dawnzera for hereditary angioedema is a key milestone for Ionis, representing the second of four independent launches expected in the coming years.
Market OpportunitySevere hypertriglyceridemia is an indication with a high unmet need and a potential $1B+ commercial opportunity.
Market PositionDawnzera has become the HAE product with the longest dosing interval that is self-administered via an autoinjector.
Bears Say
Clinical DataDawnzera's 55% attack-rate reduction at 24 weeks is not competitive compared to Takhzyro's 87% at 26 weeks.
Competitive LandscapeHAE is a very crowded space, with upcoming competitors offering long-term durability.
Safety ConcernsThe label for Dawnzera includes a safety warning for anaphylaxis, which occurred in 2 patients during the clinical study.
Ionis Pharmaceuticals News
IONS FAQ
What was Ionis Pharmaceuticals’s price range in the past 12 months?
Ionis Pharmaceuticals lowest stock price was $23.95 and its highest was $50.43 in the past 12 months.
What is Ionis Pharmaceuticals’s market cap?
Ionis Pharmaceuticals’s market cap is $6.72B.
When is Ionis Pharmaceuticals’s upcoming earnings report date?
Ionis Pharmaceuticals’s upcoming earnings report date is Oct 30, 2025 which is in 63 days.
How were Ionis Pharmaceuticals’s earnings last quarter?
Ionis Pharmaceuticals released its earnings results on Jul 30, 2025. The company reported $0.7 earnings per share for the quarter, beating the consensus estimate of -$0.091 by $0.791.
Is Ionis Pharmaceuticals overvalued?
According to Wall Street analysts Ionis Pharmaceuticals’s price is currently Undervalued.
Does Ionis Pharmaceuticals pay dividends?
Ionis Pharmaceuticals does not currently pay dividends.
What is Ionis Pharmaceuticals’s EPS estimate?
Ionis Pharmaceuticals’s EPS estimate is -1.23.
How many shares outstanding does Ionis Pharmaceuticals have?
Ionis Pharmaceuticals has 159,391,240 shares outstanding.
What happened to Ionis Pharmaceuticals’s price movement after its last earnings report?
Ionis Pharmaceuticals reported an EPS of $0.7 in its last earnings report, beating expectations of -$0.091. Following the earnings report the stock price went up 4.556%.
Which hedge fund is a major shareholder of Ionis Pharmaceuticals?
Currently, no hedge funds are holding shares in IONS
Ionis Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.83 (44.63% Upside)
$61.83 (44.63% Upside)
Blogger Sentiment
Bullish
IONS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 208.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 5.4%
Last 30 Days ▲ 4.2%
Last 30 Days ▲ 4.2%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.89%
12-Months-Change
Fundamentals
Return on Equity
-59.83%
Trailing 12-Months
Asset Growth
10.92%
Trailing 12-Months
Company Description
Ionis Pharmaceuticals
Ionis Pharmaceuticals, Inc. is a biopharmaceutical company headquartered in Carlsbad, California, specializing in the development of innovative RNA-targeted therapies. The company focuses on treating a range of diseases, including neurological disorders, cardiovascular diseases, and metabolic conditions, with a robust pipeline of drug candidates that leverage its proprietary antisense technology. Ionis collaborates with various pharmaceutical companies to enhance drug development and expand its therapeutic reach.
IONS Company Deck
IONS Earnings Call
Q2 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call reflected strong commercial and financial performance, driven by the success of the Tryngolza launch and a robust pipeline. Despite some uncertainties in clinical study outcomes and competitive landscapes, the overall sentiment is positive due to significant revenue growth and strategic execution.View all IONS earnings summariesIONS Revenue Breakdown
60.82% R&D
39.18% Commercial
IONS Stock 12 Month Forecast
Average Price Target
$61.83
▲(44.63% Upside)
Technical Analysis
Alkermes
―
Cytokinetics
―
Sarepta Therapeutics
―
Axsome Therapeutics
―
Krystal Biotech
―
Ownership Overview
0.82% Insiders
43.25% Mutual Funds
0.25% Other Institutional Investors
40.90% Public Companies and Individual Investors